1. Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies
- Author
-
Samuel W. Kazer, Jose Ordovas-Montanes, Svend Kjaer, Pascal Poignard, Carol Fong, Irene Sanjuan Nandin, Alex K. Shalek, Facundo D. Batista, Daryl W. Borley, Simone Pecetta, Eric Meffre, Cecilia Deantonio, Juan A. Torreno-Pina, Daniel Lingwood, Paula Maldonado, Francesca Gasparrini, Usha Nair, Julia Coleman, and Dennis R. Burton
- Subjects
0301 basic medicine ,medicine.drug_class ,Technical Advances ,Immunology ,Hemagglutinin (influenza) ,Monoclonal antibody ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,medicine ,Immunology and Allergy ,Research Articles ,biology ,Tetanus ,Immunogenicity ,Toxoid ,Correction ,medicine.disease ,Influenza A virus subtype H5N1 ,3. Good health ,030104 developmental biology ,biology.protein ,Antibody ,030215 immunology - Abstract
Sanjuan Nandin et al. describe an innovative approach based on antigen-dependent activation of human memory B cells in culture. It results in the rapid generation of human antibodies against infectious agents and offers the potential for therapeutic antibody production and vaccine development., Vaccines remain the most effective tool to prevent infectious diseases. Here, we introduce an in vitro booster vaccination approach that relies on antigen-dependent activation of human memory B cells in culture. This stimulation induces antigen-specific B cell proliferation, differentiation of B cells into plasma cells, and robust antibody secretion after a few days of culture. We validated this strategy using cells from healthy donors to retrieve human antibodies against tetanus toxoid and influenza hemagglutinin (HA) from H1N1 and newly emergent subtypes such as H5N1 and H7N9. Anti-HA antibodies were cross-reactive against multiple subtypes, and some showed neutralizing activity. Although these antibodies may have arisen as a result of previous influenza infection, we also obtained gp120-reactive antibodies from non–HIV-infected donors, indicating that we can generate antibodies without prior antigenic exposure. Overall, our novel approach can be used to rapidly produce therapeutic antibodies and has the potential to assess the immunogenicity of candidate antigens, which could be exploited in future vaccine development.
- Published
- 2017